
Fungus deadly to bats found in Colorado's Rocky Mountain National Park, crosses Continental Divide
A deadly fungal disease impacting bat populations has now been detected west of the Continental Divide in Colorado for the first time, raising concerns among wildlife officials. While Colorado has already identified White Nose Syndrome in Colorado in different parts of the state, the detection of the fungus Pseudogymnoascus destructans in bat guano at the Holzwarth Historic Site on the west side of the Rocky Mountain National Park adds to the growing concern for bat populations.
"It means that the fungus is continuing to spread throughout Colorado," Michelle Verant Wildlife Veterinarian with the National Parks Service, explained. "All previous cases in the state were on the eastern part... this is the first detection of the fungus West of the Continental Divide in Grand County, Colorado."
National Park Service
White-Nose Syndrome thrives in the cold temperatures where bats hibernate. The fungus grows on their skin, particularly their wings and face, causing damage that often leads to death before the bats can emerge from hibernation in the spring.
Verant explained that bats play a crucial role in maintaining healthy ecosystems, eating insects by the thousands each night, helping to control pests like mosquitoes, moths, beetles, and crickets – some of which are significant agricultural threats. According to a study, the economic impact of bats is also significant. Studies estimate that bats provide $3 billion to $22 billion each year in pest control services to North American farmers.
While WNS has caused massive population collapses on the east coast, to the tune of 90% in some cases, according to Verant, Colorado has yet to see that kind of devastation. That doesn't mean scientists are not actively monitoring Colorado bats for a crisis just like that, now that Pd is in the state. A small glimmer of hope comes from the idea that western bat species may have natural defenses against the spread of the fungus.
"Western bats tend to hibernate in more dispersed locations like rocky outcrops and crevices, unlike the large colonies found in eastern caves and mines," said Verant. This difference in hibernation habits could potentially slow the spread of the fungus, as fewer bats are bumping into each other, with a chance to spread WNS.
However, Verant cautions that in many cases, once the fungus arrives, severe disease and death follow within a few years.
Since Colorado is home to multiple bat species, each with unique behaviors, Verant said understanding how the disease affects each species is critical. Those differences could also lead to an unexpected defense. In the meantime, humanity is still working to create a solution to stop the spread of the fungus, with researchers focusing efforts on developing tools to help bats survive the disease, including antifungal compounds, environmental sprays, and even a vaccine that can boost bat immune systems.
"It's really depressing to see such a dramatic loss of these fascinating and valuable creatures," Verant said. "It will be important to continue monitoring this colony to understand if and when bats develop disease and suffer impacts from that."
If you find a dead or injured bat, do not handle it. Please report it to Colorado Parks and Wildlife at 303-291-7771 or email Wildlife.Batline@state.co.us.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
June full moon this week has major lunar standstill. Won't happen again until 2043
June's full moon promises to be a special sight, if Mother Nature cooperates. June's full moon will be at its lowest point since 2006 since we're in the middle of a major lunar standstill. You'll have to wait awhile before it rolls around again; It won't happen again until 2043. If you're outside, the moon will appear larger than normal low on the horizon and may even be orange or reddish. Here's what to know. The next full moon will be on Wednesday, June 11, with the peak occurring at 3:44 a.m. ET. 'The June full Moon got the name 'strawberry moon' from a number of North American native tribes, since the wild strawberry reaches peak ripeness and is ready for harvesting in June,' according to the Farmers Almanac. "Because of the importance of the wild strawberry as a spring food staple, the name 'Strawberry Moon' was given to the June full moon by the Algonquin, Ojibwe, Dakota, Lakota, Chippewa, Oneida, and Sioux tribes." June's full moon will be special. "In the Northern Hemisphere, it will be the lowest full moon seen until 2043, staying unusually close to the horizon " according to the Old Farmer's Almanac. Look for the full moon at 3:44 a.m. ET June 11, about 22 degrees above the southern horizon. "When the moon is low in the sky it appears especially big." The last time the full moon was this low was 18.6 years ago, according to in what's known as a major lunar standstill. It won't happen again until 2043. As the moon shines through the thick layer of air, it may appear golden, orange, or even reddish. June's full moon is the closest full moon to the summer solstice, which falls on June 21 this year. The summer solstice marks the longest day of the year in the Northern Hemisphere. Look toward the southern horizon at 3:44 a.m. ET on June 11. Can't pull yourself out of bed? You can see it later but that's the time it will reach its peak. Make sure you have a clear view since the moon will only be about 22 degrees above the horizon. "Every day, the moon rises in the east and sets in the west, but the location of the moonrise and moonset on the horizon changes, moving from north to south to north again over the course of a month. Throughout the 18.6-year lunar cycle, the northernmost and southernmost extremes also change," said. "During a major lunar standstill, the northernmost and southernmost moonrise and moonset are at their farthest distance apart. This affects how long the moon appears to stay in the sky." Called a 'major lunar standstill,' the natural phenomenon doesn't take place over one day but over about two years when the moon rises and sets at more northerly and southerly spots along the horizon, said. According to the remaining full moons of 2025 are: Thursday, July 10: 4:37 p.m. ET, buck moon Saturday, Aug. 9: 3:55 a.m. ET, sturgeon moon Sunday, Sept. 7: 2:09 p.m. ET, corn moon Monday, Oct. 6: 11:48 p.m. ET, hunter's moon (super moon) Wednesday, Nov. 5: 8:19 a.m ET., beaver moon (super moon) Thursday, Dec. 4: 6:14 p.m. ET, cold moon (super moon) The summer solstice occurs at 10:41 p.m. ET, June 20 this year. The solstice marks the exact time when the sun reaches it northernmost point in the sky, according to EarthSky. In the Northern Hemisphere, the June solstice marks the shortest night and longest day of the year. This article originally appeared on Treasure Coast Newspapers: June full moon is June 11. How to view in Florida lunar standstill


Indianapolis Star
3 hours ago
- Indianapolis Star
Caitlin Clark injury update: When will Fever star return? 'We're gonna play the long game'
INDIANAPOLIS – Caitlin Clark will not play in Tuesday's game at Atlanta, Fever coach Stephanie White said on Monday. Clark's status for the game, which come just over two weeks after she suffered a quad strain, was previously up in the air. Clark didn't rule out playing in the game in her availability on June 3, but said she would need to be re-evaluated and left it up to the Fever's medical staff to make the final decision. Now, that question has been answered. "Not for tomorrow, no," White said Monday when asked if Clark would be available on Tuesday. Personal touches, secret messages: Behind the scenes of making Caitlin Clark's new Wilson basketballs Clark suffered a quad strain sometime during the Fever's game against the New York Liberty on May 24, though she couldn't pinpoint the specific play it happened. She reported some pain after the game and got an MRI, which showed a strain in her left quad. 'Obviously, adrenaline covers up a lot of stuff when you're in the heat of battle,' Clark said during her media availability on June 3. 'And after the game, I had some pain, and then we got an MRI, and that kind of gave me the result that I didn't want to see. But, you know, those types of things don't lie.' Clark's original timeline was that she would be out for two weeks before she would be re-evaluated, setting her re-evaluation date at June 8. She was evaluated this weekend and allowed to begin some aspects of practice again, White said, but not necessarily cleared for basketball activities at the highest level. "I don't know if cleared is the right word, I mean, she's ready to start ramping back up," White said. "But it's completely different when you're just doing 1-on-1 workouts, and when you're out there in 5-on-5, getting up and down the floor, moving laterally. So she's been allowed to do some practicing, not everything. And we're gonna be smart, and we're gonna be cautious, and we're gonna play the long game." Clark participated in the portion of practice open to media Monday afternoon, which were shooting drills from midrange and 3-point range. They went around the arc as a team, making shots from each corner, each wing and the top of the key. Clark didn't seem limited in that portion of practice, running for rebounds and shooting as normal. But shooting drills are much different than actual practice — both in the amount of contact and the intricacies of it. "It's one thing to do some shooting drills," White said. "It's another thing to get out there on the floor, get back into movement patterns, rhythm, timing, and so that's what part of, you know, picking and choosing things that they can be in in practice, so that we can see their progression." White did not provide a specific timeline for Clark's return to the court. The Fever play at Atlanta on Tuesday, then return to Indianapolis and a have a few days off before playing the New York Liberty on Saturday. No, the Fever star will miss her fifth straight game as she recovers from a quad injury. Coach Stephanie White confirmed Monday that Clark would not play on Tuesday.
Yahoo
10 hours ago
- Yahoo
Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals
TAIPEI, June 9, 2025 /PRNewswire/ -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, and Taiwan-based Formosa Pharmaceuticals ("Formosa", today announced a licensing agreement, whereby Harrow has acquired the exclusive U.S. commercial rights for BYQLOVI™ (clobetasol propionate ophthalmic suspension) 0.05%. BYQLOVI was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of post-operative inflammation and pain following ocular surgery and is the first new ophthalmic steroid in its class in over 15 years. Harrow expects BYQLOVI to be available in the fourth quarter of 2025. "We are thrilled to soon launch BYQLOVI, a truly clinically differentiated topical corticosteroid, into a U.S. market that now exceeds 7 million annual ophthalmic surgeries," said Mark L. Baum, Chief Executive Officer of Harrow. "With compelling efficacy, extraordinary safety, and patient‑friendly dosing, BYQLOVI has the potential to shift the paradigm in the multi-billion-dollar U.S. post-surgical care ophthalmic segment." "Harrow's commitment to innovation, patient access, and physician engagement closely aligns with our mission to promote unique clinical advancements that improve patient outcomes," said Erick Co, President and CEO of Formosa Pharmaceuticals. "We are confident that Harrow's leadership in the U.S. eyecare space will ensure BYQLOVI's successful adoption among surgeons and eyecare professionals – and ultimately, better post-surgical experiences for U.S. patients." BYQLOVI, a high-potency ophthalmic corticosteroid formulated using Formosa's proprietary APNT® nanoparticle formulation technology, delivers a highly uniform suspension that minimizes particle setting and provides consistent dosing. Its pharmacologic performance and clinical outcomes position it as a best‑in‑class option for post-operative inflammation and pain. Key highlights of BYQLOVI include: Best-in-Class Pain Relief with 77% and 85%, respectively, of patients in supportive pivotal clinical studies reporting no pain at Day 4 post-surgery; 82% and 87%, respectively, reporting no pain at Day 8 post-surgery. Best-in-Class Inflammation Clearance with 33% and 30%, respectively, of patients in supportive pivotal clinical studies with zero cell counts in the anterior chamber at Day 8 post-surgery. Safety Benefits with only 1.4% of patients experiencing elevated intraocular pressure (IOP), a substantially lower rate compared to other ophthalmic steroids. Best-in-Class Post-Surgical Dosing at 1 drop BID dosing for 14 days on label; without the need for a loading dose and a maintenance phase. About BYQLOVI™ (clobetasol propionate ophthalmic suspension) 0.05% BYQLOVI (clobetasol propionate ophthalmic suspension) 0.05%, for topical ophthalmic use INDICATIONS AND USAGE BYQLOVI is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery. CONTRAINDICATIONS BYQLOVI is contraindicated in most active viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. WARNINGS AND PRECAUTIONS Intraocular Pressure (IOP) Increase: Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. If this product is used for 10 days or longer, IOP should be monitored. Cataracts: Prolonged use of corticosteroids may result in posterior subcapsular cataract formation. Delayed Healing: The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation. Corneal and Scleral Melting: In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids. The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy, and where appropriate, fluorescein staining. Bacterial Infections: Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, steroids may mask infection or enhance existing infection. If signs and symptoms fail to improve after 2 days, the patient should be reevaluated. Viral Infections: Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). Fungal Infections: Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal culture should be taken when appropriate. ADVERSE REACTIONS Ocular adverse reactions occurring in ≥ 1% of subjects in clinical studies who received BYQLOVI included eye inflammation (2%), corneal edema (2%), anterior chamber inflammation (2%), cystoid macular edema (2%), intraocular pressure elevation (1%), photophobia (1%) and vitreous detachment (1%). Many of these reactions may have been the consequence of the surgical procedure. USE IN SPECIAL POPULATIONS Pregnancy. There are no adequate and well-controlled studies of BYQLOVI administration in pregnant women to inform a drug-associated risk. For additional information about BYQLOVI™, please see the Full Prescribing Information. About Formosa Pharmaceuticals Formosa Pharmaceuticals, Inc. ( is a clinical stage biotechnology company with primary focus in the areas of ophthalmology and oncology. The company's proprietary nanoparticle formulation technology (APNT®), through which BYQLOVI was developed, improves the dissolution and bioavailability of APIs for topical, oral, and inhaler administration. Resulting formulations have high uniformity, purity, and stability, thereby allowing the utilization of poorly soluble or extremely potent drug agents which otherwise may face insurmountable challenges in safety, delivery, and penetration to target tissues. For more details about Formosa Pharma and APNT®, visit About Harrow Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its portfolio of pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visit Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward-looking statements." Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, risks related to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks, including litigation matters, and other uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general; physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. These and additional risks and uncertainties are more fully described in Harrow's filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2023, subsequent Quarterly Reports on Form 10-Q, and other filings with the SEC. Such documents may be read free of charge on the SEC's web site at Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. View original content to download multimedia: SOURCE Formosa Pharmaceuticals Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data